We are proud to work collaboratively with a number of corporate partners to generate vital income for Retina UK, whilst giving our community the opportunity to explore new and innovative technology, and support the pharmaceutical industry in their mission to evidence the need for vital treatments.
We are very grateful to the following corporate partners for all they do to support our work and our community:
A new corporate partner for 2019, Novartis has supported Retina UK through project funding and event sponsorship. Novartis holds the European licence for the first ever commercially available gene therapy for an inherited retinal dystrophy – Luxturna – designed to treat sight loss caused by mutations on the RPE65 gene.
OXSIGHT is a long-standing corporate partner of Retina UK and supports the delivery of our vital information and support services. OXSIGHT produces a range of smart glasses designed for people with peripheral vision loss, sometimes known as tunnel vision. The glasses use innovative technology to enhance and increase the quality and field of vision.
Another new corporate partner for 2019, PROQR has supported Retina UK through project funding and event sponsorship. Their research and development pipeline includes pre-clinical and clinical trials relating to Leber congenital amaurosis (LCA) 10, Usher syndrome type 2a and autosomal dominant RP caused by a particular mutation in the rhodopsin (RHO) gene.
We’d love to hear from you if you are interested in working with us. We take a flexible and personalised approach to our relationships with corporate supporters – give Fiona a call on 01280 815900 or email fiona.leahy@RetinaUK.org.uk for an informal chat.